Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Vania Hungria, MD, PhD
Associate Professor
Department of Hematology, Clinica São Germano, São Paulo, Brazil
Sao Paulo, United States